Champions Oncology Inc (NASDAQ:CSBR), a technology-enabled oncology research organisation, announced on Monday that it has expanded its clinical bioanalytical services with the integration of multiple Cytek Aurora flow cytometers.

The company has also appointed Troy Tremaine, MBA, to lead Bioanalytical Commercial Strategy.

New Cytek Aurora instruments enhance Champions' spectral and conventional flow cytometry capabilities, enabling higher-complexity spectral analysis and deeper service offerings for clients. Troy Tremaine brings decades of commercial leadership experience in preclinical and bioanalytical services across multiple therapeutic areas.

Champions Oncology provides end-to-end oncology R&D solutions to biopharma companies, leveraging the largest annotated bank of patient-derived xenograft (PDX) and primary haematological malignancy models. Its portfolio of bioanalytical platforms, data analytics and proprietary in vivo and ex vivo models supports global preclinical and clinical oncology drug discovery and development.